Nanobac Pharmaceuticals, Inc. announces Scientists Discover Nanobacterium in Ovarian Cancer Patients.

Business Editors/Health/Medical Writers

TAMPA, Fla.--(BUSINESS WIRE)--Nov. 24, 2003

Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP) ("Nanobac" or "The Company"). Austrian Scientists from University Hospital in Vienna, utilizing diagnostics developed and provided by Nanobac OY, reported finding Nanobacterium in Ovarian cancer patients. The discovery was published in the APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica) Journal; APMIS 111: 951-4, 2003. This study investigated whether nanobacteria are associated with microcalcifications (i.e., psammoma bodies) found in ovarian cancers. Positive nanobacterial results were found in all 7 microcalcificed specimens by immunohistochemical staining, transmission electron microscopy, ELISA, and infrared spectroscopy. Control cases of ovarian adenocarcinomas without microcalcifications were negative for nanobacteria. The scientists concluded that Nanobacterial infection may be of clinical importance as these bacteria are related to microcalcifications in ovarian cancer.

"Because Nanobacteria are the only known self replicating crystallizing molecule, and a significant percentage of degenerative human diseases involve pathological calcifications, these findings represent significant validation of our company's intellectual property," said John Stanton, Chairman and CEO. "Further, we are on a path to rapidly explore all research, development and collaborative opportunities involving nanobacteria science."

Nanobac OY is the Research and Development arm of the Company and is located in Kuopio, Finland. The discovery of Nanobacteria was originally documented and patented by Dr.'s Olavi Kajander and Neva Ciftcioglu, the Founders of Nanobac OY. Nanobac OY provides the principal scientific research support and diagnostic technology segment of Nanobac.

Nanobac is a leader in the research of diagnosis and treatment of degenerative diseases stemming from nanobacterial infections. This infection is implicated in the formation of disease-causing calcification and plaque in the circulatory system and vital organs. Nanobac markets diagnostics and prescription nanobiotic medications demonstrated to safely and effectively treat an underlying cause of atherosclerosis, coronary heart disease and other degenerative diseases.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A. For more information, please visit our website at http://www.nanobaclabs.com or contact us at [e-mail].

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which might cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report, these statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.